# Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

> **NCT01437449** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 27 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Cetuximab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01437449
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2018-09-11
- **Final completion:** 2019-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01437449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01437449, "Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01437449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*